Dr. Frederick Sancilio reports

LOBE SCIENCES LTD. COMMENTS ON WHITE HOUSE EXECUTIVE ORDER SUPPORTING DRUG DEVELOPMENT FOR NEUROLOGICAL AND MENTAL HEALTH DISORDERS

Lobe Sciences Ltd. has welcomed the recent White House Executive Order supporting the advancement of novel treatments for neurological and mental health disorders.

The company believes the Executive Order represents an important step toward enabling scientific research in areas that have historically been difficult to study due to regulatory constraints. Lobe views this action as a meaningful shift toward allowing compounds to be evaluated based on their safety and clinical potential, rather than their historical classification.

"We commend the White House for recognizing the need to advance research into serious neurological and mental health conditions," said Dr. Fred Sancilio, chief executive officer and chairman of Lobe Sciences. "We believe that many investigational compounds should ultimately be removed from Schedule I classification and studied within standard pharmaceutical development frameworks. This would allow the scientific community to more effectively evaluate their potential to address significant unmet medical needs."

Lobe's subsidiary, Cynaptec Pharmaceuticals, is developing L-130 as a non-hallucinogenic drug product candidate as the industry continues to better understand this class of compounds. L-130 is currently being advanced for the treatment of chronic cluster headache and substance use disorder.

The company believes this evolving regulatory environment may stimulate broader research efforts and accelerate the development of new therapies for patients with serious neurological and mental health disorders.

About Lobe Sciences Ltd.

Lobe Sciences is a clinical-stage biotechnology company focused on advancing promising drug candidates through key stages of development in a cost- and time-efficient manner. The company identifies high-potential programs at an early stage and progresses them toward meaningful value milestones across multiple therapeutic areas, with a focus on underserved markets.

Lobe Sciences operates through a capital-efficient, subsidiary-based model, including a majority interest in Cynaptec Pharmaceuticals Inc. and its wholly owned subsidiary, Applied Lipid Technologies Inc.

About Cynaptec Pharmaceuticals Inc.

Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders. Cynaptec's initial development program is focused on the use of its proprietary L-130 (psilocin mucate) compound for treatment of the significant unmet medical needs of patients with chronic cluster headache, with an additional preliminary proof of concept to assess potential utility for substance use disorders. Cynaptec is 64 per cent owned by Lobe.

About L-130 (psilocin mucate)

L-130 is a novel, patented, oral and stable form of psilocin, the active metabolite of the pro-drug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions. Whereas conventional psilocin is an unstable compound that has been challenging for the industry to develop as a stand-alone pharmaceutical, L-130's stability and bioavailability profile, and associated safety and efficacy signals, suggest the potential for prescription drug development in a variety of neurological and psychiatric indications.

We seek Safe Harbor.